• Hui-Hsin Ko, Shih-Lung Cheng, Jang-Jaer Lee, Hsin-Ming Chen, Mark Yen-Ping Kuo, and Shih-Jung Cheng.
• Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan.
• Head Neck. 2017 Jul 1; 39 (7): 1327-1332.

BackgroundAldo-keto reductase family 1 member B10 (AKR1B10) is implicated in xenobiotic detoxification and has disparate functions in tumorigenesis that are dependent on the cell types. The purpose of this study was to investigate the clinicopathological significance of AKR1B10 as a prognostic marker for oral squamous cell carcinomas (OSCCs).MethodsAKR1B10 protein expression was analyzed by immunohistochemistry in 77 patients with OSCC.ResultsThe AKR1B10 labeling score for OSCCs (1.16 ± 1.14) was significantly higher than that for normal oral mucosa (0.10 ± 0.23; p < .0001). High expression of AKR1B10 significantly correlated with large tumor size (p = .041), advanced TNM classification (p = .037), and patient's areca quid chewing habit (p = .025). Multivariate analysis revealed that high AKR1B10 labeling score >1.16 (hazard ratio, 3.647; p = .001) significantly correlated with mortality.ConclusionAKR1B10 overexpression is an independent poor prognostic biomarker for OSCC. AKR1B10 inhibitors may be promising in clinical trials against OSCC. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1327-1332, 2017.© 2017 Wiley Periodicals, Inc.

41 keywords...

hide…